Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants

Mise à jour : Il y a 4 ans
Référence : NCT00314041

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines. Booster phase: To compare the safety of and production of antibodies by MnCC with and without MMR and to compare the antibody response to that produced by a low dose of plain polysaccharide vaccine as a way of investigating immune memory


Critère d'inclusion

  • Meningitis, Meningococcal

Liens